Search NLS News

OligoNova, Sweden’s national initiative for oligonucleotide therapies, is gathering leading Swedish oligonucleotide experts for its first face-to-face network conference. The conference is to be held at GoCo Health innovation City in Mölndal on April 25-26, 2022. The primary aims of this gathering of researchers, clinicians and innovators, representing approximately 40 research groups from across Swedish […]

Residential exposure to ambient air pollutants is linked to an elevated risk of SARS-CoV-2 infection, an observational study of young adults in Stockholm, Sweden shows. The study was conducted by researchers from Karolinska Institutet. They examined the link between estimated exposure to air pollutants at home addresses and positive PCR tests for SARS-CoV-2 in young […]

The Novo Nordisk Foundation (NNF) will focus on three key themes in the years to 2030, people’s health, the sustainability of society and the planet and boosting Denmark’s life science ecosystem. “The COVID-19 pandemic, the world-wide spread of diabetes and the climate changes emphasize the need for a global effort to safeguard people’s health and […]

Bavarian Nordic has announced the dosing of the first subject in the Phase 3 VANIR clinical trial of its investigational respiratory syncytial virus (RSV) vaccine candidate, MVA-BN RSV in older adults. The VANIR trial is a global, randomized, double-blind Phase 3 trial of the recombinant MVA-BN RSV vaccine in 20,000 adults aged 60 years and […]

Genmab and AbbVie have announced topline results from the first cohort of the EPCORE NHL-1 clinical trial evaluating epcoritamab (DuoBody-CD3xCD20), an investigational subcutaneous bispecific antibody. The study cohort includes 157 patients with relapsed/refractory large B-cell lymphoma (LBCL) who received at least two prior lines of systemic therapy, including 38.9 percent who received prior treatment with […]

Orion Corporation’s Board of Directors has appointed Liisa Hurme as President and CEO of Orion Corporation and the Chair of the Executive Management Board of the Orion Group as of 1 November 2022, until which her predecessor Timo Lappalainen will hold the position. “We began an international recruitment process for a new CEO immediately after […]

Lundbeck recently completed a global Phase IV, randomized, comparative study exploring the role of vortioxetine as a treatment option between SSRIs and serotonin–noradrenaline reuptake inhibitors (SNRIs). The efficacy of vortioxetine was directly compared to one of the latest introduced SNRIs, desvenlafaxine, as monotherapy. The study, called VIVRE, recruited a total of 605 patients across 12 […]

BioArctic has announced that the company’s partner AbbVie has decided to terminate its collaboration with BioArctic regarding the portfolio of alpha-synuclein antibodies, including ABBV-0805. BioArctic and AbbVie have collaborated since 2016 regarding the research and development of BioArctic’s portfolio of alpha-synuclein antibodies for Parkinson’s disease and other potential indications. In 2019, a Phase 1 study […]

Ilya Pharma has made a strategic investment in its supply chain to facilitate development of its ILP pipeline by acquiring one of its long-term partners, Nordic Bioanalysis. Founded in 2010, Nordic Bioanalysis have established a strong reputation both in the Nordics and internationally as experts in bioanalytical development and validation for pharmaceuticals, classic small molecules […]

Spago Nanomedical has received notice from the Japanese Patent Office (JPO) that it intends to grant the company’s patent application including a critical component of the SpagoPix candidate drug SN132D. JPO has issued a Notice of Allowance which means the patent will be granted following confirmation of Spago Nanomedical and payment of applicable fees. The […]